Phathom Pharmaceuticals (PHAT) Non-Current Deffered Revenue (2022 - 2026)

Phathom Pharmaceuticals (PHAT) has 5 years of Non-Current Deffered Revenue data on file, last reported at $347.9 million in Q1 2026.

• Non-Current Deffered Revenue for Q1 2026 came in at $347.9 million, up 1.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $347.9 million (up 1.19% YoY), and the FY2025 annual result was $350.1 million, up 5.06% from the prior year.
• Non-Current Deffered Revenue retreated to $347.9 million in Q1 2026 per PHAT's latest filing, from $350.1 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $350.1 million in Q4 2025 and troughed at $109.5 million in Q4 2022.
• A 5-year average of $282.3 million and a median of $322.4 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2023 and 2026: Non-Current Deffered Revenue soared 173.74% in 2023, then increased 1.19% in 2026.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $109.5 million in 2022, then jumped by 173.74% to $299.8 million in 2023, then advanced by 11.16% to $333.3 million in 2024, then increased by 5.06% to $350.1 million in 2025, then slipped by 0.64% to $347.9 million in 2026.
• Business Quant data shows PHAT's Non-Current Deffered Revenue at $347.9 million in Q1 2026, $350.1 million in Q4 2025, and $349.0 million in Q3 2025.